Position in GNLX
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$605,000
New position
Shares Held
250,000
first reported quarter
Ownership
0.558%
of shares outstanding
% of Portfolio
0.49%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026CM Management, LLC holds $27,887,100 across 17 Biotechnology names. GNLX ranks #11 (2.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RIGL |
Rigel Pharmaceuticals Inc
|
235,000 | $6,354,400 | |
| 2 | RPRX |
Royalty Pharma plc
|
125,000 | $5,996,250 | |
| 3 | CHRS |
Coherus Oncology, Inc.
|
2,100,000 | $3,549,000 | |
| 4 | ELDN |
Eledon Pharmaceuticals, Inc.
|
650,000 | $2,002,000 | |
| 5 | AVIR |
Atea Pharmaceuticals, Inc.
|
355,000 | $1,909,900 | |
| 6 | IOVA |
Iovance Biotherapeutics, Inc.
|
450,000 | $1,579,500 | |
| 7 | COYA |
Coya Therapeutics, Inc.
|
375,000 | $1,477,500 | |
| 8 | XOMA |
XOMA Royalty Corp
|
40,000 | $1,254,800 |
All Filings in GNLX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $605,000 | 250,000 | Shares | Sole | 2026-05-08 | |
| No filing history on record for this holder in this stock. | ||||||